Vesifin 5 and 10 mg FC tablets
PDF Leaflet Revision Date: 31 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of overactive bladder syndrome.
Dosage (summary)
5 mg once daily, may increase to 10 mg once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Potent CYP3A4 inhibitors (e.g., ketoconazole)
- Anticholinergic drugs
Contraindications
- Hypersensitivity to solifenacin
- Urinary retention
- Uncontrolled narrow angle glaucoma
- Myasthenia gravis
- Toxic megacolon
- Severe renal impairment
- Severe hepatic impairment
- Prolonged QT interval
Common side effects
- Dry mouth
- Constipation
- Dizziness
- Blurred vision
Counselling Points
- Take orally with or without food.
- May cause blurred vision; caution with driving.
- Report any allergic reactions.
Serious warnings
- QT prolongation risk
- Angioedema
- Anaphylactic reactions
Important Disclaimer
The Vesifin 5 and 10 mg FC tablets professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
